Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice.

Breccia M, Abruzzese E, Castagnetti F, Bonifacio M, Gangemi D, Sorà F, Iurlo A, Luciano L, Gozzini A, Gentile M, Bocchia M, Luzi D, Maggi A, Sgherza N, Isidori A, Crugnola M, Pregno P, Scortechini AR, Capodanno I, Pizzuti M, Foà R.

Ann Hematol. 2018 Sep;97(9):1577-1580. doi: 10.1007/s00277-018-3337-2. Epub 2018 Apr 19.

PMID:
29675611
2.

Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib.

Efficace F, Castagnetti F, Martino B, Breccia M, D'Adda M, Angelucci E, Stagno F, Cottone F, Malato A, Trabacchi E, Capalbo SF, Gobbi M, Visani G, Salvucci M, Capodanno I, Tosi P, Tiribelli M, Scortechini AR, Levato L, Maino E, Binotto G, Gugliotta G, Vignetti M, Baccarani M, Rosti G.

Cancer. 2018 May 15;124(10):2228-2237. doi: 10.1002/cncr.31323. Epub 2018 Mar 2.

3.

The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia.

Galimberti S, Bucelli C, Arrigoni E, Baratè C, Grassi S, Ricci F, Guerrini F, Ciabatti E, Fava C, D'Avolio A, Fontanelli G, Cambrin GR, Isidori A, Loscocco F, Caocci G, Greco M, Bocchia M, Aprile L, Gozzini A, Scappini B, Cattaneo D, Scortechini AR, La Nasa G, Bosi A, Leoni P, Danesi R, Saglio G, Visani G, Cortelezzi A, Petrini M, Iurlo A, Di Paolo A.

Oncotarget. 2017 Sep 30;8(50):88021-88033. doi: 10.18632/oncotarget.21406. eCollection 2017 Oct 20.

4.

Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories.

Perricone M, Palandri F, Ottaviani E, Angelini M, Bagli L, Bellesia E, Donati M, Gemmati D, Zucchini P, Mancini S, Marchica V, Trubini S, De Matteis G, Di Zacomo S, Favarato M, Fioroni A, Bolzonella C, Maccari G, Navaglia F, Gatti D, Toffolatti L, Orlandi L, Laloux V, Manfrini M, Galieni P, Giannini B, Tieghi A, Barulli S, Serino ML, Maccaferri M, Scortechini AR, Giuliani N, Vallisa D, Bonifacio M, Accorsi P, Salbe C, Fazio V, Gusella M, Toffoletti E, Salvucci M, Svaldi M, Gherlinzoni F, Cassavia F, Orsini F, Martinelli G.

Oncotarget. 2017 May 16;8(20):32608-32617. doi: 10.18632/oncotarget.15940.

5.

Spontaneous recurrent hematuria and hematospermia: Unique manifestations of von Willebrand disease type I. Case report.

Minardi D, Scortechini AR, Milanese G, Leoni P, Muzzonigro G.

Arch Ital Urol Androl. 2016 Mar 31;88(1):62-3. doi: 10.4081/aiua.2016.1.62.

6.

Results of a prospective phase II trial with oral low-dose bexarotene plus photochemotherapy (PUVA) in refractory and/or relapsed patients with mycosis fungoides.

Rupoli S, Canafoglia L, Goteri G, Leoni P, Brandozzi G, Federici I, Micucci G, Giantomassi F, Mozzicafreddo G, Alterini R, Filosa G, Ricotti G, Simonacci M, Scortechini AR, Zizzi A, Pimpinelli N.

Eur J Dermatol. 2016 Jan-Feb;26(1):13-20. doi: 10.1684/ejd.2015.2672.

PMID:
26678311
7.

Dasatinib first-line: Multicentric Italian experience outside clinical trials.

Breccia M, Stagno F, Luciano L, Abruzzese E, Annunziata M, D'Adda M, Maggi A, Sgherza N, Russo-Rossi A, Pregno P, Castagnetti F, Iurlo A, Latagliata R, Cedrone M, Di Renzo N, Sorà F, Rege-Cambrin G, La Nasa G, Scortechini AR, Greco G, Franceschini L, Sica S, Bocchia M, Crugnola M, Orlandi E, Guarini A, Specchia G, Rosti G, Saglio G, Alimena G.

Leuk Res. 2016 Jan;40:24-9. doi: 10.1016/j.leukres.2015.11.008. Epub 2015 Nov 17.

PMID:
26643920
8.

Thrombosis in essential thrombocytemia and early/prefibrotic primary myelofibrosis: the role of the WHO histological diagnosis.

Rupoli S, Goteri G, Picardi P, Micucci G, Canafoglia L, Scortechini AR, Federici I, Giantomassi F, Da Lio L, Zizzi A, Honorati E, Leoni P.

Diagn Pathol. 2015 Apr 16;10:29. doi: 10.1186/s13000-015-0269-1.

9.

Mobilization-driven postconsolidation therapy in elderly patients with acute myeloid leukemia: feasibility and efficacy of autologous stem cell transplantation versus low-dose gemtuzumab ozogamicin.

Capelli D, Chiarucci M, Poloni A, Saraceni F, Mancini G, Trappolini S, Troiani E, Montanari M, Scortechini I, Offidani M, Rupoli S, Scortechini AR, Gini G, Discepoli G, Leoni P, Olivieri A.

Biol Blood Marrow Transplant. 2014 Sep;20(9):1399-406. doi: 10.1016/j.bbmt.2014.05.019. Epub 2014 May 28.

10.

Cardiovascular events and intensity of treatment in polycythemia vera.

Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, De Stefano V, Elli E, Iurlo A, Latagliata R, Lunghi F, Lunghi M, Marfisi RM, Musto P, Masciulli A, Musolino C, Cascavilla N, Quarta G, Randi ML, Rapezzi D, Ruggeri M, Rumi E, Scortechini AR, Santini S, Scarano M, Siragusa S, Spadea A, Tieghi A, Angelucci E, Visani G, Vannucchi AM, Barbui T; CYTO-PV Collaborative Group.

N Engl J Med. 2013 Jan 3;368(1):22-33. doi: 10.1056/NEJMoa1208500. Epub 2012 Dec 8.

11.

Efficacy and safety of pegylated liposomal doxorubicin in primary cutaneous B-cell lymphomas and comparison with the commonly used therapies.

Pulini S, Rupoli S, Goteri G, Pimpinelli N, Alterini R, Bettacchi A, Mulattieri S, Picardi P, Tassetti A, Scortechini AR, Fioritoni G, Leoni P.

Eur J Haematol. 2009 Mar;82(3):184-93. doi: 10.1111/j.1600-0609.2008.01197.x.

PMID:
19215609
12.

Coexistence of two discordant B-cell lymphomas in the skin and lymph node: report of a case with primary cutaneous follicle-center lymphoma and nodal mantle-cell lymphoma.

Goteri G, Rupoli S, Stramazzotti D, Discepoli G, Scortechini AR, Giacchetti A, Morichetti D, Tassetti A, Pulini S, Mulattieri S, Stronati A, Leoni P.

Br J Dermatol. 2007 Sep;157(3):629-31. Epub 2007 Jun 26. No abstract available.

PMID:
17596170
13.

Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas.

Pulini S, Rupoli S, Goteri G, Pimpinelli N, Alterini R, Tassetti A, Scortechini AR, Offidani M, Mulattieri S, Stronati A, Brandozzi G, Giacchetti A, Mozzicafreddo G, Ricotti G, Filosa G, Bettacchi A, Simonacci M, Novelli N, Leoni P.

Haematologica. 2007 May;92(5):686-9.

14.

Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma.

Offidani M, Corvatta L, Piersantelli MN, Visani G, Alesiani F, Brunori M, Galieni P, Catarini M, Burattini M, Centurioni R, Ferranti M, Rupoli S, Scortechini AR, Giuliodori L, Candela M, Capelli D, Montanari M, Olivieri A, Poloni A, Polloni C, Marconi M, Leoni P.

Blood. 2006 Oct 1;108(7):2159-64. Epub 2006 Jun 8.

PMID:
16763209
15.

Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study.

Offidani M, Corvatta L, Marconi M, Visani G, Alesiani F, Brunori M, Galieni P, Catarini M, Burattini M, Centurioni R, Rupoli S, Scortechini AR, Giuliodori L, Candela M, Capelli D, Montanari M, Olivieri A, Piersantelli MN, Leoni P.

Haematologica. 2006 Jan;91(1):133-6.

16.

Long-term experience with low-dose interferon-alpha and PUVA in the management of early mycosis fungoides.

Rupoli S, Goteri G, Pulini S, Filosa A, Tassetti A, Offidani M, Filosa G, Mozzicafreddo G, Giacchetti A, Brandozzi G, Cataldi I, Barulli S, Ranaldi R, Scortechini AR, Capretti R, Fabris G, Leoni P; Marche Regional Multicentric Study Group of Cutaneous Lymphomas.

Eur J Haematol. 2005 Aug;75(2):136-45.

PMID:
16000130
17.

Comparison of two regimens for the treatment of elderly patients with acute lymphoblastic leukaemia (ALL).

Offidani M, Corvatta L, Malerba L, Marconi M, Catarini M, Centurioni R, Leoni F, Scortechini AR, Masia MC, Leoni P.

Leuk Lymphoma. 2005 Feb;46(2):233-8.

PMID:
15621806
18.

Expression of c-myb and B-myb oncogenes on myelofibrotic marrow fibroblasts.

Scortechini AR, Rupoli S, Piccinini G, Luchetti MM, Cantori I, Gabrielli A, Leoni P.

Leuk Lymphoma. 1999 Apr;33(3-4):295-304. Erratum in: Leuk Lymphoma 1999 Sep;35(1-2):following 2.

PMID:
10221509
19.

[Biologic aspects and clinical use of granulocyte growth factor].

Rupoli S, Battelli N, Del Prete S, Salvi A, Cinciripini A, Scortechini AR, Cantori I, Barulli S, Leoni P.

Recenti Prog Med. 1995 Dec;86(12):510-7. Review. Italian.

PMID:
8588087
20.

[Idiopathic myelofibrosis. Main pathogenetic, prognostic and therapeutic aspects].

Barulli S, Rupoli S, Cinciripini A, Scortechini AR, Cantori I, Leoni P.

Recenti Prog Med. 1995 Jul-Aug;86(7-8):312-9. Review. Italian.

PMID:
7569290

Supplemental Content

Loading ...
Support Center